LYEL · Lyell Immunopharma, Inc.
$15.53
+0.18 (+1.17%)
At close · Aug 21
Market Cap
$380.56M
Shares
24.51M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.53
Open$15.54
Day$15.20–16.16
52W close$10.65–38.60
Avg vol 30d165K
Short int1.2M · 5.0% float · 8.7d
Short vol53%
Last earningsAug 6, 2026
DataJun 2025–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Jun 2, 2025; bars on opposite sides are not compared.
Up next
Next earnings call
Oct 19, 2026
Est · unconfirmed
· in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
+13%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
17%
mid-range
Momentum
relative strength
1-month return
+23%
trailing
6-month return
−36%
trailing
YTD return
−50%
this year
Relative strength
−47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $20 — 200d above 50d
Institutional flow
Accumulating
+16% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$42.6K over 90 days · 100% sells
Short interest
Rising
5.03% of float · ▲ +0.9% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
88 holders — mid 3-yr range
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
−41%
Y/Y
EPS growth
+39%
Y/Y
Free cash flow
$-150.8M
Balance sheet
$60.2M
net cash
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
+13%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
17%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $20 — 200d above 50d
Institutional flow
Accumulating
+16% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$42.6K over 90 days · 100% sells
Short interest
Rising
5.03% of float · ▲ +0.9% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
88 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $11
Now $16 · 17%
Range high $39
vs 200-day avg -24%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LYEL
this stock
Lyell Immunopharma, Inc.
|
$380.56M | -49.5% | -41.0% | — | 5.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jun 2, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LYEL | +11.3% | +23.0% | -35.6% | +20.0% | -49.6% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +12.7% | +19.3% | -47.1% | +17.5% | -61.8% |
Key facts
CIK
1806952
CUSIP
55083R203
13F (30d)
88 filings
87 filers
Visit website
Investor relations